(firstQuint)The Cardiovascular Protective Effects of Febuxostat in Peritoneal Dialysis Patients.

 Patients with more than 3-month-history of peritoneal dialysis and hyperuricemia.

 Use Febuxostat to control their serum uric acid for 1 year.

 To observe the cardiovascular events of patients, and compare and evaluate the changes of heart function, heart construction, serum cardiac markers and brain natriuretic peptide (BNP) levels before and after Febuxostat treatment.

.

 The Cardiovascular Protective Effects of Febuxostat in Peritoneal Dialysis Patients@highlight

The purpose of this study is to determine whether Febuxostat could protect cardiovascular function of peritoneal dialysis patients by lowering serum uric acid.

